Radioactive iodine does not significantly reduce recurrence in low-risk differentiated thyroid cancerRadioactive Iodine May Not Prevent Recurrence in Low-Risk Thyroid Cancer

Endocrinology, diabetes & metabolism Published September 8, 2026 Study authors: Asif Maheen, Nisar Mudasar, Asif Aliza, Batool Makzooma, Iqbal Rabia Javed, Amin Mohammed Hammad Jab… PubMed ↗ DOI ↗ Editorial oversight: Dr. Lars van Dijk, PhD · Surgical, Procedural & Diagnostic

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that radioactive iodine does not significantly reduce recurrence in low-risk differentiated thyroid cancer.

This meta-analysis evaluated the efficacy of radioactive iodine (RAI) compared to no radioactive iodine in 5260 patients with low-risk differentiated thyroid cancer (DTC) following total thyroidectomy. The primary outcome of recurrence showed no statistically significant difference (OR 0.66; 95% CI: 0.41-1.08; p = 0.10). Similarly, 5-year recurrence-free survival did not show a statistically significant difference (OR 2.47; 95% CI: 0.63-9.62; p = 0.19).

Secondary outcomes, including treatment response (OR 1.00; 95% CI: 0.52-1.92; p = 1.00), serum thyroglobulin levels (OR 1.20; 95% CI: 0.00-342.55; p = 0.95), and elevated thyroglobulin antibodies (OR 0.91; 95% CI: 0.38-2.16; p = 0.83), also showed no statistically significant differences. Side effects such as xerostomia and dysphonia were noted but did not reach statistical significance in the analysis.

Authors noted limitations including heterogeneity across studies, variability in outcome definitions, and a predominance of observational data. The findings suggest that routine RAI ablation may not provide a clear, clinically meaningful benefit for patients classified as low-risk DTC. Clinical application of these results is tempered by the lack of precision in some estimates and the mixed nature of the included data.

How this fits prior evidence

This meta-analysis addresses the role of radioactive iodine in low-risk differentiated thyroid cancer. While previous evidence notes that hemithyroidectomy is associated with a 3% higher risk difference in cancer recurrence rate, this meta-analysis of 5260 patients finds no statistically significant difference in recurrence for those receiving radioactive iodine versus no radioactive iodine. It provides a specific look at post-thyroidectomy management for low-risk patients.

A large review of data involving over 5,000 patients looked at the role of radioactive iodine (RAI) for those with low-risk differentiated thyroid cancer. The study specifically looked at patients who had already undergone a total thyroidectomy to see if adding RAI helped prevent the cancer from coming back.

Researchers found no statistically significant difference in cancer recurrence or five-year survival rates between patients who received radioactive iodine and those who did not. Other measures, such as treatment response and specific blood markers like thyroglobulin levels, also showed no significant differences between the two groups.

Because the data comes from a mix of different study types and has some inconsistencies, the results should be viewed with caution. The evidence currently does not show a clear, practical benefit for using routine radioactive iodine in patients classified as low-risk. Patients should discuss these findings with their medical team to determine the best plan for their specific situation.

What this means for you:

Evidence does not show a clear benefit of radioactive iodine for preventing recurrence in low-risk thyroid cancer.

Common questions

Does radioactive iodine help prevent cancer from coming back?

In this specific group of patients with low-risk differentiated thyroid cancer, the study found no statistically significant difference in recurrence rates between those who received radioactive iodine and those who did not. The results suggest that routine use of this treatment may not offer a clear benefit for preventing recurrence in low-risk cases.

What are the potential side effects of radioactive iodine?

The study noted potential side effects such as xerostomia (dry mouth) and dysphonia (difficulty speaking). However, the data did not show a statistically significant difference in the occurrence of these issues between patients who received the treatment and those who did not.

Who is this finding relevant for?

This finding is specifically relevant for patients diagnosed with low-risk differentiated thyroid cancer who have already undergone a total thyroidectomy. Because the evidence is not definitive, you should consult your doctor to discuss how these findings apply to your specific health needs.

Study Details

Study typeMeta analysis

EvidenceLevel 1

Follow-up60.0 mo

PublishedSep 2026

PMID42522170

View Original Abstract ↓

BACKGROUND: Radioactive iodine (RAI) therapy is often administered post-total thyroidectomy in patients with low-risk differentiated thyroid carcinoma, despite guidelines advising against its routine application. Evidence regarding the efficacy of RAI in reducing recurrence and improving survival in low-risk differentiated thyroid cancer (DTC) remains inconsistent. METHODS: We conducted a systematic review and meta-analysis of observational studies and randomized clinical trials that compare RAI versus no RAI in low-risk DTC patients. Databases such as MEDLINE, Scopus, Cochrane Library, and Google Scholar were searched through December 2025. Outcomes included recurrence, recurrence-free survival, treatment response, biochemical markers, and side effects. We performed statistical analysis using Review Manager (RevMan) 5.4 with a random-effects model, reporting odds ratios (OR) with 95% confidence intervals, and significance set at p < 0.05. Heterogeneity was assessed using I statistics. RESULTS: Ten studies (n = 5260) were included in the analysis. No statistically significant difference was observed between the two groups for recurrence (OR 0.66, 95% CI: 0.41-1.08; p = 0.10), 5-year recurrence-free survival (OR 2.47, 95% CI: 0.63-9.62; p = 0.19), or treatment response (excellent response: OR 1.00, 95% CI: 0.52-1.92; p = 1.00). Secondary outcomes, including serum thyroglobulin > 1 ng/mL (OR 1.20, 95% CI: 0.00-342.55; p = 0.95), elevated thyroglobulin antibodies (OR 0.91, 95% CI: 0.38-2.16; p = 0.83), xerostomia (OR 5.63, 95% CI: 0.05-667.24; p = 0.48), and dysphonia (OR 0.96, 95% CI: 0.53-1.72; p = 0.88), were also not significantly different between groups, although estimates were not precise. CONCLUSION: The available randomized and observational evidence does not demonstrate a clear, clinically meaningful benefit of routine RAI ablation in patients classified as low-risk DTC. These findings should be interpreted with caution due to heterogeneity across studies, variability in outcome definitions, and the predominance of observational data.

Radioactive iodine does not significantly reduce recurrence in low-risk differentiated thyroid cancerRadioactive Iodine May Not Prevent Recurrence in Low-Risk Thyroid Cancer

How this fits prior evidence

Common questions

Study Details

Global GJB2 mutation prevalence in nonsyndromic hearing impairment

One in four people with hearing loss carries a specific gene mutation

Clinical research that matters. Delivered to your inbox.

Radioactive iodine does not significantly reduce recurrence in low-risk differentiated thyroid cancerRadioactive Iodine May Not Prevent Recurrence in Low-Risk Thyroid Cancer

How this fits prior evidence

Common questions

More on differentiated thyroid cancer

Study Details

Global GJB2 mutation prevalence in nonsyndromic hearing impairment

One in four people with hearing loss carries a specific gene mutation

Clinical research that matters. Delivered to your inbox.

Related in ENT (Otolaryngology)

From Other Specialties